When Pfizer set out to lobby for its proposed buyout of AstraZeneca, CEO Ian Read made a point of reassuring Britain’s political establishment that it will keep a large portion of R&D operations in the U.K. But it never bothered to clarify what its plans are in Sweden.

…read more

Source: Global R&D centers brace for new blows as Pfizer circles AstraZeneca


0 No comments